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Abstract
Background: Spinal Muscular Atrophy (SMA) is a neurodegenerative motor neuron disorder resulting from a homozygous
mutation of the survival of motor neuron 1 (SMN1) gene. The gene product, SMN protein, functions in RNA biosynthesis in
all tissues. In humans, a nearly identical gene, SMN2, rescues an otherwise lethal phenotype by producing a small amount of
full-length SMN protein. SMN2 copy number inversely correlates with disease severity. Identifying other novel biomarkers
could inform clinical trial design and identify novel therapeutic targets.
Objective:: To identify novel candidate biomarkers associated with disease severity in SMA using unbiased proteomic,
metabolomic and transcriptomic approaches.
Materials and Methods:: A cross-sectional single evaluation was performed in 108 children with genetically confirmed SMA,
aged 2–12 years, manifesting a broad range of disease severity and selected to distinguish factors associated with SMA type
and present functional ability independent of age. Blood and urine specimens from these and 22 age-matched healthy
controls were interrogated using proteomic, metabolomic and transcriptomic discovery platforms. Analyte associations
were evaluated against a primary measure of disease severity, the Modified Hammersmith Functional Motor Scale (MHFMS)
and to a number of secondary clinical measures.
Results: A total of 200 candidate biomarkers correlate with MHFMS scores: 97 plasma proteins, 59 plasma metabolites (9
amino acids, 10 free fatty acids, 12 lipids and 28 GC/MS metabolites) and 44 urine metabolites. No transcripts correlated
with MHFMS.
Discussion: In this cross-sectional study, ‘‘BforSMA’’ (Biomarkers for SMA), candidate protein and metabolite markers were identified.
No transcript biomarker candidates were identified. Additional mining of this rich dataset may yield important insights into relevant
SMA-related pathophysiology and biological network associations. Additional prospective studies are needed to confirm these
findings, demonstrate sensitivity to change with disease progression, and assess potential impact on clinical trial design.
Trial Registry: Clinicaltrials.gov NCT00756821.
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Spinal Muscular Atrophy (SMA) is a monogenic, recessively
inherited neuromuscular disorder caused by loss-of-function
mutation of the Survival Motor Neuron 1 (SMN1) gene [1]. A
neighboring nearly-identical copy of this gene, SMN2, is
invariably present in individuals with SMA. SMN2 produces
transcripts that are predominantly spliced to a truncated form in
which exon 7 is deleted. However, some full-length transcript is
generated that produces normal full-length SMN protein. SMN2
partially ameliorates disease in SMA, as the number of SMN2
copies inversely correlates with phenotypic severity [2]. Much
attention has thus been directed to potential therapies that
increase synthesis of full-length protein from the SMN2 gene [3–
10]. Of the clinical trials to date performed using available FDA-
approved pharmaceuticals with ability to increase SMN expres-
sion in vitro, none have demonstrated apparent efficacy against
placebo [11–14]. These medications, sodium phenylbutyrate,
valproic acid and hydroxyurea, increase full length SMN
transcript and protein but apparently not to a sufficient degree
to demonstrate clinical benefit in clinical trials to date. These
medications were not specifically designed for treatment of SMA.
Potential limitations of these studies also include not knowing the
optimal dosage or duration of the study, and whether the putative
increase in SMN protein will help rescue a pool of non-
functioning but alive motor neurons or stabilize the existing pool
of functioning motor neurons and limit the rate of further clinical
decline. Several new SMA therapeutics that are expressly
designed to upregulate SMN are in different stages of develop-
ment and biomarkers are thus urgently needed to assist in their
advancement [15].
Identification, validation and qualification of biomarkers that
correlate with disease severity will have a substantial impact on
SMA basic and clinical science in multiple ways. The clinical
course of SMA poses challenges to clinical trial design [16–18].
Across the range of disease severity and onset age, most
individuals with SMA manifest three broad phases over the
course of their disorder. An initial presymptomatic phase is
followed by an early symptomatic phase characterized by either
frank regression in strength or function or a failure to achieve
normally expected developmental gross motor milestones. This is
then followed by a chronic plateau phase characterized by a
variable period of stability or much slower decline in function
over a period of several months to years. This pattern of evolution
of symptoms, and the potentially variable points along their
course at which individuals with SMA may enter trials, makes it
challenging to decide which endpoints, cohorts and trial duration
will be most effective in determining whether or not a given
therapeutic intervention is of value. SMA biomarkers could
substantially improve the performance of clinical trials by (1)
expanding the population of potential study subjects by reducing
‘‘floor’’ and ‘‘ceiling’’ effects of current measures, (2) permitting
‘‘early look’’ assessment of treatment futility or predicting clinical
response in otherwise prolonged duration trials, (3) easing the
burden of travel and outcome assessment in medically fragile
patients, and (4) enabling simpler, more cost effective and
efficient clinical trial design.
In addition, biomarkers found in an unbiased manner can be
used to develop hypotheses about cellular pathophysiology, or
validate hypotheses derived from basic science studies of SMN
biology. The cellular basis of specific motor neuron vulnerability to
low SMN protein levels remains puzzling as SMN is expressed in
all tissues, and is essential to eukaryotic mRNA splicing [19–22].
Hints of special neuronal vulnerability to defects in RNA handling
are emerging with the identification of other putative RNA-related
genes [23–25] as the cause of motor neuron disorders [26].
Identification of biomarkers (or a correlated biomarker network)
that associate with SMA disease severity could identify abnormal
signaling pathways, constrained essential substrates, or toxic
products that have pathophysiologic importance. Biomarkers
identified by an unbiased approach may also lead to important
clues that would be missed by other approaches through
identification of novel factors affecting or associated with disease
severity.
While SMN transcript or protein levels are obvious biomarkers
for therapeutics targeting SMN production (see companion paper,
Crawford, et al. [61]), there are compelling reasons why SMA
biomarker discovery should be expanded beyond SMN. Measures
of SMN expression in blood may not reflect the critical level of
expression of the protein in the CNS. A wide variability or
fluctuations of transcript and protein analysis of SMN levels in
blood may undermine its value as a clinical tool. Moreover, SMN
expression as an outcome biomarker identifies factors acting only
at that aspect of pathogenesis, missing those factors downstream of
SMN abundance that might influence phenotype. An unbiased
approach to biomarker identification includes the prospect of
identifying potential targets of therapy downstream of SMN
production.
Recent advances in bioanalytical technology and informatics
have enabled systems level biomarker discovery efforts based on
metabolomics, transcriptomics, and proteomics [27] (hereafter
referred to as ‘‘-omics’’). The present ‘‘BforSMA’’ (Biomarkers for
SMA) project is a comprehensive -omics investigation of unprec-
edented scale and scope. Traditionally, previous studies of
neurodegenerative disorders have tended to be hypothesis-based
efforts focused upon markers representing preselected pathophys-
iologies [28–30]. Or, in prior studies that were unbiased to disease
mechanism, evaluations were performed on cohorts with signifi-
cant potential confounders [31,32]. Often, these studies have been
conducted in a manner that was insensitive to markers of disease
severity, rate of progression, or disease stage at time of sample
acquisition [32–35] or were restricted to evaluation of either small-
molecule metabolites, proteins, transcript expression profiles [30–
32,34–37], or a subset of these [37].
The BforSMA project combines three elements designed to
maximize the potential to identify scientifically and clinically
relevant novel biomarkers. The first of these is an unbiased
metabolomics, proteomics, and transcriptomics analysis of
samples obtained at a single time point. The second includes
recruitment of a well-characterized disease cohort, free of
potential confounding variables, encompassing a relatively broad
range of disease phenotype to account for the singular
characteristics of SMA variability and clinical course. The third
is the inclusion of an age-matched normal control cohort for
secondary class-specific comparisons [38]. The resulting
BforSMA data set is intended to be hypothesis-generating, and
thus may include false positive ‘‘hits’’ in order not to exclude
potentially important biomarkers. The cross-platform dataset
derived from this project is expected to provide a rich resource to
spur future investigations.
This unbiased discovery project for biomarkers of SMA
function is one of two biomarker projects performed on the same
cohort in parallel. The other, specifically targeting measures of
SMN expression in blood, is presented separately (see companion
paper, Crawford, et al. [61]). In this report we describe the overall
project design, characteristics of the recruited cohort, and provide
a first level analysis of non-SMN biomarkers correlated with
multiple functional outcome measures.
Biomarkers in Spinal Muscular Atrophy
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Planning and Objectives
The primary objective was to identify biomarkers associated
with gross motor function as measured by the Modified Hammer-
smith Functional Motor Scale (MHFMS) [39] across a broad
range of clinical phenotypic severity in children with SMA types I,
II, and III. Secondary objectives were to identify (1) biomarkers
associated with the other clinical characteristics identified in
Table 1 and Table S1, (2) class biomarkers that distinguish SMA
from normal age-matched controls, and (3) networks of biomarker
associations that suggest specific biochemical or signaling path-
ways of potential import to SMA pathogenesis. SMN-related
measurements and correlations are detailed in the accompanying
Table 1. Clinical data of SMA and Control Subjects.
SMA Type I SMA Type II SMA Type III Control p-value* p-value*
N=17 N=49 N=42 N=22 I vs IIvs III SMA vs Control
Age
mean (SD) 5.70 (3.54), 6.55 (3.40), 7.51 (3.11), 6.95 (3.29), 0.14 0.84
median [range] 4.03 [2.4–12.7] 6.49 [2.2–13.0] 7.42 [2.4–13.0] 6.02 [2.2–13.0]
Sex, n( % ) 0.73 0.64
Male 10 (59%) 26 (53%) 20 (48%) 10 (46%)
2–5 years old 6 15 7 5
6–12 years old 4 11 13 5
Female 7 (41%) 23 (47%) 22 (52%) 12 (54%)
2–5 years old 5 9 8 6
6–12 years old 2 14 14 6
MHFMS,
mean (SD) 0 (0) 14.02 (10.5) 34.1 (10.0) 39.8 (0.7) ,0.001 ,0.001
median [range] 0 [0–0] 11 [0–36] 40 [2–40] 40 [37–40]
Current Motor Function,
n( % )
,0.001 ,0.001
Sit 0 (0%) 42 (85.7%) 41 (97.6%) 22 (100%)
Walk 0 (0%) 0 (0%) 32 (76.2%) 22 (100%)
Feeding Method ,0.001 0.07
solid food 1 (5.9%) 44 (89.8%) 41 (97.6%) 22 (100%)
modified oral intake 2 (11.8%) 2 (4.1%) 1 (2.4%) 0 (0%)
G-tube fed 14 (82.4%) 3 (6.1%) 0 (0%) 0 (0%)
BMI z-Score 0.04 0.17
mean (SD) 22.54 (3.98) 20.90 (4.13) 20.09 (1.65) 0.16 (1.02)
median [range] 21.34 [29.7 to 3.4] 20.12 [219.7 to 3.6] 20.05 [24.2 to 3.2] 0.34 [21.8 to 1.9]
FVC% Predicted ,0.001 0.08
mean (SD) N/A 70.04 (30.10) 104.1 (18.9) 103.3 (10.6)
median [range] N/A 66.5 [26–135] 105 [61–153] 103 [87–125]
10 meter walk
mean (SD) NA NA 10.1 (6.1) 3.5 (1.5) NA ,0.001
median [range] NA NA 9 [3.4–34] 3 [2.2–8.8]
Age of Disease Onset NA ,0.001 NA
0–6 months 17 (100%) 10 (20.4%) 1 (2.4%)
7–17 months 0 (0%) 35 (71.4%) 20 (47.6%)
18+months 0 (0%) 4 (8.2%) 21 (50.0%)
Respiratory support ,0.001 0.001
BIPAP or tracheostomy 15 (88%) 8 (16%) 0 (0%) 0 (0%)
Cough assist 1 (6%) 14 (29%) 1 (3%) 0 (0%)
*ANOVA for continuous variables; Fisher exact test for categorical variables.
There were no significant differences in age or gender across the recruitment cohorts. A key goal of this study was to minimize the confounding correlation between
present age and functional status. This goal was largely achieved, both overall and within SMA groups Type II and III, and to a partial extent, SMA Type I through a
competitive recruitment plan managed through the data coordinating center at the New England Research Institutes (NERI). The Modified Hammersmith Motor
Function Scale differentiated between SMA subjects and controls and between Type I, II and III subjects, as did respiratory support, reflecting current level of function.
FVC and the nutritional assessment score significantly distinguished between SMA type; however, BMI proved to be far less discriminatory.
doi:10.1371/journal.pone.0035462.t001
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protocols were done in accordance with GCP, IRB and local and
federal regulations.
Ethics Statement
Institutional review board (IRB) approval for the protocol was
obtained from each BforSMA clinical site before enrollment at
that site and from a central Institutional Review Board, New
England Research Institutes. Written informed consent for
participation was obtained from the legal guardians of all subjects
and assent for participation was obtained directly from subjects
whenever applicable. This trial was registered with ClinicalTrials.-
gov with identifier NCT00756821.
Study Design, Sample Size Determination and Enrollment
A cross-sectional, single visit, multi-center, exploratory study
design was employed. Blood and urine samples were collected for
biomarker analysis and DNA samples were collected for SMN2
copy number determination. No therapeutic intervention oc-
curred. The full protocol is available in the Appendix S1. Key
inclusion and exclusion criteria for this study were:
Inclusion Criteria:
For all groups:
N Age 2 to 12 years, inclusive.
N In good health in the judgment of the clinical investigator at
the time of assessment.
Specific group requirements – SMA children:
N Documented homozygous deletion of SMN1 (exon 7).
N SMA Type I defined as the inability ever to sit unaided in
the judgment of the clinical investigator.
N SMA Type II defined as the ability to ever sit unaided for
.30 seconds on a flat surface in the judgment of the clinical
investigator.
N SMA Type III defined by the ability to ever stand unaided
for 30 seconds and walk unaided for .30 ft.
Specific group requirements – Control children:
N Otherwise healthy children that may be either genetically-
related siblings of SMA children (confirmed non-carriers) or
unrelated children.
Exclusion Criteria:
For all groups:
N Systemic or specific-organ illness, including renal, hepatic,
cardiac, pulmonary, significant gastrointestinal illness, he-
matologic or rheumatic disorders requiring ongoing treat-
ment or chronic medication use.
N Any known genetic condition other than Spinal Muscular
Atrophy requiring pharmaceutical treatment.
N Use of any putative SMN-enhancing medications or
treatments for 14 days prior to enrollment including,
valproic acid, phenylbuterate, and hydroxyurea.
N Use of carnitine, creatine, oral albuterol and riluzole for
14 days prior to enrollment.
N Use of any oral prescription medications for 14 days prior to
enrollment with the exception of the following medications,
which are allowed: anti-reflux medications (e.g. rantidine),
constipation or stool softening medications (e.g. polyethylene
glycol 3350), stool bulking agents, and inhaled bronchodi-
lator medications and nebulizers (e.g. albuterol).
N Any illness requiring treatment with antibiotics or anti-
inflammatory medication within the past 14 days.
N Participation in a clinical trial (except observational studies)
within the previous 14 days.
The number and type of subjects to be enrolled was based upon
clinical and statistical considerations. An age range of 2 to 12 years
was chosen in an attempt to limit confounding factors associated
with developmental maturation or inability to reliably perform the
outcome measures in the youngest children, and metabolic
changes associated with puberty at the older age ranges. Subjects
were required to have a documented homozygous deletion of exon
7 in the SMN1 gene. There was special emphasis on enrolling
children as subjects across the range of phenotype severity that fall
within the eligibility criteria.
Clinical definitions of SMA type were based upon maximum
achieved gross motor function (see inclusion criteria, above). This
is revised from the classification initially proposed by Munsat et al.
[40], and further modified by Zerres et al. [41].
Individuals were excluded from enrollment if they had any
illness or were on any the categories of medications considered
possible confounders to interpretation of the data within 2 weeks of
their participation (see exclusion criteria, above). Subjects were
eligible for enrollment if those medications or supplements had
been discontinued at least 2 weeks prior to the study visit.
An unbalanced number of subjects from the three types of SMA
was targeted (17 Type I, 45 Type II, and 40 Type III SMA
subjects) in part out of concern that recruitment of eligible subjects
with SMA Type I would be difficult because of their high level of
inter-current illness and mortality in childhood and the lower age
limit specified. Given the floor effects of the MHFMS in this
population, all subjects with Type I, regardless of severity, would
receive a score of 0. The sample size for the SMA subjects was
selected to achieve 83% power for the primary outcome of
MHFMS to detect a biomarker set associated with motor function
using multivariate elastic net regression analysis [42], assuming a
0.75 correlation between the observed and theoretical outcomes.
The power estimate is based on an average of 100 simulated
datasets using data available from the original Hammersmith
Scale [43]. The sample size of 20 control subjects was selected to
achieve at least 90% power to detect a univariate biomarker with a
mean-fold change (MFC) of 1.5 when the false discovery rate is
controlled at 0.05 [44]. In both power calculations it was assumed
that 10% of profiled analytes are true biomarkers, and that
variance of analytes is equal to 0.2.
Sample Processing and Storage
Sample collection, handling and chain of custody procedures
were designed to ensure the best quality specimens for biomarker
analysis. We targeted collection of up to 10 mL of blood and at
least 4 mL of urine from each subject. Six milliliters of whole
blood was transferred into an EDTA tube upon collection and the
remaining blood sample was poured into a CPT tube. Four
milliliters of urine was aliquoted equally into two different
cryovials, for a total of 2 mL per cryovial. Excess urine of up to
4 mL was aliquoted into a third cryovial. EDTA tubes with 6 mL
of blood were inverted five times. Two 0.75 mL aliquots of whole
blood from the EDTA tube were put in separate cryovials to make
the DNA and RNA samples. CPT tubes with 4 mL of blood were
gently inverted 8–10 times and centrifuged at 3,000RPM for 25
minutes at room temperature (18–25uC). The CPT tubes were
gently inverted again for 5–10 times. The PBMC layer was poured
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the central lab, PPD, Inc. (Kentucky). DNA, RNA, and urine
samples were transported on dry ice and stored in a 270uC/-80uC
freezer. PBMC samples were stored at room temperature. Protein
and small molecule metabolites from plasma and urine samples
were analyzed by BG Medicine, Inc. (Waltham, MA), and mRNA
exons and transcripts from blood by Expression Analysis, Inc.
(Durham, NC). Statistical analyses were performed by BG
Medicine and NERI.
Experimental Platforms
Proteomics. The quantitative discovery proteomics workflow
was based on multi-dimensional liquid chromatography – MS/MS
analyses of peptides combined with 8-plex iTRAQ labeling [45].
To achieve sufficient dynamic range of plasma analysis and long-
term reproducibility, a two-stage protein depletion method was
optimized [46]. In the first depletion stage, 14 abundant plasma
proteins are depleted by an IgY14 antibody column (Sigma-
Aldrich, St. Louis, MO, USA) (serum albumin, IgG, fibrinogen,
transferrin, IgA, IgM, haptoglobin, a-2-macroglobulin, a-1-acid
glycoprotein, a-1-antitrypsin, Apo A-I, Apo A-II, complement C3,
and Apo B-100) The flow-through was further depleted by a
Supermix column (Sigma-Aldrich), which retains moderately
abundant proteins with a broad specificity. Proteins in the
Supermix flow-through are recovered on a reversed-phase
column.
Protein samples were reduced with TCEP, alkylated with
iodoacetamide, and digested with trypsin. Following digestion
each sample is labeled with a discrete iTRAQ reagent. Six of the
eight channels were utilized for primary samples and two were
used for reference samples created by combining aliquots from
each primary sample in the study. Labeled samples were
combined into an iTRAQ mix and fractionated by strong cation
exchange into six fractions. Each of the fractions were further
fractionated by HPLC and spotted on MALDI plates for MSMS
analysis using an AB/SCIEX 4800 TOF/TOF mass spectrometer
(MDS SCIEX, Concord, ON, Canada). Acquisition of LC-MSMS
data was optimized by in-house developed algorithms to select and
measure consistent sets of peptides from experiment to experi-
ment.
Relative quantification of peptides was carried out by
determining relative intensities of reporter ions between the
sample specific channels (m/z 114, 115, 116, 118, 119, 121) and
reference sample channels (m/z 113, 117). The average ratios
relative to the two reference channels were used in most
experiments.
Identification of peptides from the MS/MS spectra was
achieved using the Mascot database searching tool [47] and a
BGM-developed validation protocol to distinguish true and false
positive peptide matches. Once data collection was completed for
every study sample, peptides were assigned to a minimum non-
redundant protein set. Relative quantification of proteins was
achieved by assigning the median ratio from peptides mapped to
the given protein. Normalization of protein expression data was
carried out using a procedure described by Vandersompele et al.
[48].
Transcriptomics. RNA was isolated using the Ambion
RiboPure
TM blood kit (Austin, TX, USA) according to manufac-
turer’s instructions. Two amplification steps were performed using
the NuGEN Ovation Pico WTA system protocol (San Carlos,
CA, USA). cDNA purification columns were used after the SPIA
and post Exon modules.
105 SMA and 21 control subject samples were measured for
exon array analysis using the Affymetrix GeneChip Human Exon
1.0 ST Array (Fremont, CA, USA). Affymetrix probe sets were
normalized using the RMA method [49].
Metabolomics. Metabolomics profiling was conducted on
organic extracts of plasma samples using multiple analytical
platforms. Plasma lipids were analyzed by LC/MS profiling on a
QStar Elite Quadrupole Time-of-Flight instrument (MDS/
SCIEX, Concord, ON, Canada). Amino acid analysis (AAA)
was carried out as a targeted analysis of 42 species using Multiple
Reaction Monitoring (MRM) on a 4000Qtrap instrument (MDS/
SCIEX, Concord, ON, Canada). Free fatty acid (FFA) analysis
targeted 57 free – unesterified – fatty acids by GCMS following the
methylation of these compounds. GC/MS of plasma and urine
samples was completed in a semi-targeted fashion: a list of analyte
targets was created from a preliminary profiling experiment. The
target peaks were then measured in all of the study samples. This
platform used an Agilent single-quadrupole mass analyzer (Model
5975, Agilent, Santa Clara, CA). The lipid and GC/MS platforms
used a set of universal internal standards (5–8 non-endogenous
compounds) for quantification. The amino acid analysis (AAA)
and free fatty acid (FFA) platforms relied on calibrated internal
standards for each of the target compounds thereby facilitating
absolute quantification.
To facilitate the generation of reproducible data, analytical runs
were organized into batches. The batch size is defined by the
number of samples that can be comfortably prepared for mass
spectrometric analysis in less than a day. To be able to correct for
batch-to-batch variations and to identify within-batch drifts in the
analytical performance, technical replicates of a Quality Control
(QC) sample are inserted at a regular interval into the run
sequence. These QC samples were prepared from pooling an
equal aliquot from each primary sample in the study. The QC
samples are processed identically to the primary samples and
results for the QC samples are used to monitor data quality. The
order of acquisition of the primary samples was determined by a
randomization scheme to minimize the occurrence and effect of
systematic variations in/on workflow performance.
The FFA platforms uses isotope labeled fatty acid standards for
absolute quantification. 41 out of the 57 targeted compounds
reported by the method have their own internal standard and 16
additional fatty acids are determined against a calibration curve
shared with another compound. In this platform fatty acids are
converted into their form methyl esters and analyzed by GC/MS.
Lipid Profiling. Lipid measurements were performed on all
129 primary samples in the BforSMA study as well as 24 reference
(QC) samples (153 samples in total). Analysis of the 153 samples
was completed in three batches.
Plasma samples were extracted with a solvent of 25%:10%:65%
dichloromethane:isopropanol:methanol. All samples (primary and
QC) were spiked with five internal standards that were used to
track platform performance and for data normalization: 14:0 LPE,
17:0 LPC, 24:0 PC, 40:0 PC, and 51:0 TG.
LC/MS profiles of the samples were processed with a set of
pipelined procedures for (LC) peak detection, peak alignment, and
peak family clustering to consolidate multiple ionized forms of a
lipid into a single component, normalization, and batch correc-
tion. Aligned components were quantified in terms of their
processed peak intensities.
Identification of lipid components was completed by a
combination accurate mass-retention time matching to known
lipid species characterized previously at BGM and by LC-MS/MS
analysis of the lipid extracts. Additionally, adduct pattern and
nitrogen-rule were utilized to establish the unambiguous identity of
the detected lipids.
Biomarkers in Spinal Muscular Atrophy
PLoS ONE | www.plosone.org 5 April 2012 | Volume 7 | Issue 4 | e35462Amino Acid Analysis. The AAA platform targeted 42 L-
amino acids (including all essential amino acids). Methanol
extracts of the plasma samples (10 mL) were labeled with an
iTRAQ reagent (Applied Biosystems, Foster City, CA, USA)
producing the m/z 115 reporter fragment. Known concentrations
of amino acid standard labeled with the m/z 114 reagent were
added to the sample and analyzed by LC-MRM. For each amino
acid target to transitions were monitored: MH
+2. 114 for the
internal standard and MH
+2. 115 for the unknown. The
intensity ratio of the peaks, m/z 115/m/z 114, scaled with the
known concentration of the standard yielded the amino acid
concentrations in mM units.
Amino Acid Analysis (AAA) data were generated for all 129
primary samples as well as 24 reference samples (153 samples in
total). Samples were processed in three batches. Peak integration
was performed using MultiQuant (MDS/SCIEX) software. The
concentration of each detected amino acid was calculated using
the in-house data processing pipeline.
Gas Chromatography/Mass Spectrometry (GC/MS)
Analysis. For GC/MS analysis plasma samples (50 mL) or
dried urine samples (from 250 mL urine) were extracted with
methanol. Dried extracts were trimethylsilylated (TMS of
hydroxyl-, carboxyl-, and amino-functionalities), and oximated
(oxo- functionalities), in order to make analytes volatile for GC
separation. To improve analytical precision the injections were
made in duplicate and the mean intensities were recorded. 128
primary samples and 54 QC samples were processed in 9 batches.
Due to the inherent complexity involved in analyte assignment
to peaks identified in GC/MS, a target peak list, was carried
through the analysis. Peak intensities were normalized to one of
the 8 internal standards added to each sample. The most
appropriate internal standard for each analyte was based on
determining which internal standard exhibited the lowest
variability in the QC samples for that given analyte. Peak
normalization and batch correction were performed by pipelined
procedures. Following statistical analysis of the data to determine
marker status, identification of unknown analytes was carried out
based on a priority list. Stronger markers (in terms of p-values)
were assigned higher priorities than weaker markers or non-
markers. Identification of unknown analytes was attempted by a
combination of matching to GC/MS library spectra (in terms of
retention time and fragment masses), de novo interpretation, and
purchasing standard compounds and comparing fragmentation
pattern. Since plasma analytes were better represented in our GC/
MS library than urine analytes, a better identification rate could
be achieved for plasma analytes (,70% versus ,50% in urine).
Free Fatty Acid Analysis. Free fatty acids – fatty acids not
esterified to lipids – were measured by GC/MS of the
corresponding fatty acyl methylesters in a format of isotope
dilution measurements. 41 of the 57 target compounds were
calibrated against their own isotope labeled internal standards and
the remaining analytes were calibrated against one of the 48
standards.
Free fatty acid (FFA) analysis was obtained on 129 primary
samples as well as 10 reference or QC samples. The project was
completed in two batches. Because of the chemical stability of
these compounds including the internal standards, batch correc-
tion was not necessary for this platform and the relatively small
number of QC samples was utilized only for assessing the
reproducibility of the measurements.
Data Analysis
A summary of continuous and categorical outcome measures is
provided in Table S1.
Univariate Continuous Outcomes. The set of seven (7)
univariate continuous outcomes collected includes the Modified
Hammersmith Functional Motor Scale (MHFMS), Age at Disease
Onset (eight categories: 0–3 months, 4–6 months, 7–11 months,
12–17 months, 18–23 months, 24–35 months, 3-6 years, 6–12
years; treated as a continuous variable), BMI Z-score, Forced Vital
Capacity (FVC), 10 Meter Timed Walk Test, SMN Protein Levels
and SMN2 Copy Number. The predictor variables are analyte
concentration (absolute concentration where available, or relative
concentration otherwise) and potential confounders include age
and gender. A univariate multiple linear regression model (LM)
was fitted. Analytes with fewer than 20 complete measurements
were excluded from this analysis. The linear regression model may
be written as:
Yi~b0zb1Xizb2ageizb3genderizei,eieN 0,s2   
where i
indicates the i
th subject, Y is the outcome of interest; Xi is the
analyte intensity in natural log scale. The intercept ß0, coefficient
for analyte amount ß1, coefficient for age and gender ß2,ß3 and
variance s
2 of the error term ei were estimated.
Univariate Categorical Outcomes. The set of eight (8)
univariate categorical outcomes includes SMA type (two catego-
ries: disease and control; three categories: Type I, Type II, Type
III; and four categories: Type I, Type II, Type III and Control),
Current Level of Function (3 categories: non-sitters, sitters,
walkers; and 5 categories: Type I, Type II non-rolling, Type II
rolling, Type III non-stair climbing, Type III stair climbing), Age
at Disease Onset (3 categories: 0–6 months, 7–17 months, $ 18
months), Nutritional Assessment (two categories: modified intake/
G-tube fed and solid food), Respiratory Support (4 categories;
none, cough assist, Bi-level Positive Airway Pressure, (BiPAP)
,16 hrs, BiPAP .16). The goal was to test whether the analyte
abundance is similar across all the categorical levels, adjusting for
potential confounding factors of age and gender. If this test was
rejected (i.e. a difference does exist), the divergent categories were
identified. For this purpose, an analysis of covariance model
(ANCOVA) was fitted to the data. Analytes that were measured in
fewer than ten subjects in either category being compared were
excluded from analysis. The ANCOVA model can be written as:
Yij~mzaizb2ageijzb3genderijzeij,eijeN 0,s2   
...where
i indicates the i
th factor level, j indicates the j
th subject in the i
th
factor level, Yij is the analyte abundance for the j
th subject in the i
th
factor level. ai is the factor level effect subject to P
ai~0,i~0,:::,c;j~1,:::,niAll analytes were first tested for
difference of abundance across all categories.
H0 : a1~a2~:::~ac~0
Ha : NotallaiequalzeroIf the abundance of an analyte was
found to differ across factor levels, pairwise comparisons of factor
level means were subsequently performed to assess these differ-
ences (e.g. sign, and magnitude).
H0 : ai~ai;
Ha : ai=ai;
The analyte was declared a candidate marker if both the overall
test and at least one of the pairwise comparisons were statistically
significant.
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tests of statistical significance with hundreds of analytes across all
bioanalytical platforms were performed simultaneously. There-
fore, some tests were likely to have significant results by chance
alone, resulting in false discoveries. In order to control the false
discovery rate (FDR) among all significant findings, we applied the
method described in Benjamini and Hochberg [50], which
transforms the individual p-values into FDR-corrected p-values.
Analytes were classified as markers if the p-value was less than 0.05
and the FDR-adjusted p-value was less than 0.10.
Results
Characteristics of the Study Cohort
A total of 130 subjects enrolled from 18 sites in the United
States and Canada included 17 Type I, 49 Type II, 42 Type III
SMA, and 22 healthy control subjects. For consented subjects
undergoing study screening procedures there were 46 screen
failures. The two major reasons for screen failures were taking
prohibited medicines and lack of documented homozygous
deletion of SMN1. Enrollment figures slightly exceeded the
original targets for each group due to protocol permitted subject
replacement for insufficient quantity (n=7) or quality (n=3) of
specimens. All 18 study sites contributed at least one subject over
the course of 18 weeks concluding in March 2009. The number,
age and gender distribution of those enrolled is found in Table 1.
Although age of onset correlates with phenotype severity across the
range of individuals with SMA, a key recruitment goal of this study
was to minimize, within the ascertained cohort, the correlation
between present age and present functional status – because such
correlation might introduce an age bias into identified markers.
This goal was achieved both overall and within SMA groups Type
II and III, and to a partial extent, SMA Type I.
MHFMS scores were obtained for controls and all subjects with
SMA Type II and III, as well as 10-meter walk time for controls
and all Type III subjects able to walk (n=34). Type I subjects are
unable to perform any items on the MHFMS, and thus were
assigned the minimum MHFMS score of zero. Forced vital
capacity was available for all subjects over age 5 and/or children
able to comply with the assessment (n=69). All measures of
function, present functional state, and the historical age of disease
onset were spread over a wide range (Table 1). FVC, including
many non-ambulatory subjects assessed by the MHFMS, corre-
lated with the MHFMS, while the 10 meter walk, which assesses
those above the range of this scale, did not. BMI- z-score did not
correlate with MHFMS or age (Table 2). BMI z-score is a complex
feature that can both affect MHFMS, when obesity limits mobility,
or be affected by it, as very low muscle mass may itself reduce BMI
z-score as well as impair adequate nutrition.
Subject cooperation was an important factor in data and sample
collection in this study. In at least 14 subjects, collection of urine or
blood samples was not within strict compliance with the protocol.
Urine samples proved to be the more difficult to collect than
blood. There were no concerns identified in sample handling,
chain of custody and shipment procedures. Close attention was
paid to data quality during data collection using real-time QC
monitoring. Reproducibility of measurements was characterized
by observing the coefficients of variance (expressed in %CV)
obtained from the replicates of QC samples. Median %CVs were
around 15% of the proteomics and lipid platforms, and below
10% for GC/MS, amino acid, and free fatty acid analyses (see
Table S2).
Use of at least 12 different classes of medication (see Appendix
S2) was reported in this fragile study population. Investigators
were asked to use best clinical judgment when considering
discontinuation of medication prior to enrollment. Two subjects
were found to have been on prohibited medications post-
enrollment (methylphenidate [n=1] and glycopyrrolate [n=1]).
These samples were not excluded from the analysis, but subject to
post-hoc review for unexpected outliers that might plausibly be
associated with the medication.
Summary of Primary Analysis
Of the 1184 analytes measured across the proteomics and
metabolomics platforms, there were 490 analytes that were
significantly associated with at least one of the 11 outcome
measures or endpoints assessed in the study (Table 3). Of these,
200 analytes correlated with the MHFMS, the primary outcome
measure of this study; many were also associated with secondary
outcome measures and there were some hits seen in multiple
platforms. Table 3 shows the results of the primary outcome
analysis across the seven platforms utilized in this study. The
complete results of the univariate analyses of the MHFMS
outcome measure versus analytes across all platforms are reported
in Tables S3, S4, S5. The BforSMA data is available publically
upon publication of this report through the Neuroscience
Information Framework (http://neuinfo.org/bforsma).
To create a more manageable dataset for further evaluation and
inspection, candidate markers were prioritized for each platform
based on statistical significance of the Q-value and strength of
association with the primary outcome measure in addition to
correlations with secondary outcome measures. The top 20
markers across platforms are reported in the sections below.
Plasma Proteomics
There were 701 proteins measured in plasma across 127
samples with MALDI iTRAQ platform (one sample was lost
during processing). Of these, 151 were associated with at least one
outcome measure. 97 plasma proteins regressed against the
MHFMS. Among the top ranking candidate markers were plasma
proteins that distinguished Type II from Type III subjects, Type
III subjects from healthy controls, as well as Type I SMA subjects
from each of the other groups. Figures 1, 2, 3 shows an example of
the top 5 analytes, that discriminated between SMA types in this
study. The top 20 plasma protein hits are listed in Table 4. Ninety-
one percent (91%) of the proteins were measured with a coefficient
of variation less than or equal to 0.2, demonstrating high
measurement reproducibility. The complete list of plasma proteins
that associated with the MHFMS is available through the publicly
accessible database at http://neuinfo.org/bforsma.
Table 2. Correlations of secondary measures with MHFMS
and age for SMA subjects.
MHFMS Age
Age 0.07 (p=0.45)
BMI z-score 0.17 (p=0.09) 0.12(p=0.20)
FVC % predicted 0.70 (p,0.001) 20.14(p=0.31)
10 meter walk 20.28 (p=0.13) 20.36(p=0.045)
Of the secondary outcome measures, only forced vital capacity (FVC)
significantly correlated with the primary outcome measure – the Modified
Hammersmith Motor Function Scale. While BMI is thought to have a strong
effect on function in individuals affected by SMA, the correlation did not reach
significance here. Not surprisingly, FVC and walking were negatively correlated
with age.
doi:10.1371/journal.pone.0035462.t002
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There were 315 analytes measured across the four metabolomic
platforms; 71 in the Lipid platform, 160 in the GC/MS platform,
37 in the AAA platform and 47 in the FFA platform (Table 3). Of
these analytes, 169 were associated with at least one outcome
measure. A total of 59 analytes regressed against the MHFMS.
Table 4 shows the plasma metabolite hits in the top 20 hitlist
across the four platforms, Table 5 summarizes the total number of
statistically significant relationships these analytes have with all
outcome measures and the complete results of plasma metabolites
regression against the MHFMS is in Table S4. The complete list of
plasma metabolites ordered by the number of outcomes with
which they associate by univariate analysis is available through the
publicly accessible database at http://neuinfo.org/bforsma.
Urine Metabolomics
There were 168 metabolites measured across 123 samples with
the urine GC/MS platform. Of these 95 were associated with at
least one outcome measure. The full results of urine metabolites
regression against the MHFMS is listed in Table S5. Univariate
marker counts by outcome are listed in the publicly accessible
database at http://neuinfo.org/bforsma. Some of the analytes
declared markers using multiple outcomes, such as pantothenic
acid, glucuronic acid (Vitamin B5) and malic acid were highest
among the weaker children, whereas uric acid, glycolic acid,
xanthine, hypoxanthine, inositol, allantoin and 3-methylhistidine
were all decreased in abundance in the urine of weaker children.
The changes in levels of metabolites could be a consequence, in
part, of the specially formulated enriched diets of very weak
children.
Whole Blood Transcript Statistical Summary
Analysis of transcript data was done at both the gene expression
and exon levels. A total of 22,011 transcripts and 807,038 exons
were measured in the final data set, but no markers reached the
threshold of significance in regression against the MHFMS. The
top marker that regressed against SMA type was the NLR family
apoptosis inhibitory protein NAIP. SMN exon 7 was not found to
be significant against SMA type due to the relatively low
abundance of SMN transcript in whole blood and limits of
detection using the Affymetrix GeneChip Human Exon 1.0 ST
Array. We found the mean of all probe sets to be 10 times higher
than the mean of all SMN probe sets.
Discussion
This study provides an unbiased evaluation of potential
biomarkers in a well-characterized SMA cohort, carefully
controlled to avoid confounding factors introduced by age and
functional level. Preliminary analyses identified a rich set of more
than 400 analyte markers that regressed significantly against one
or more clinical outcome measures in the BforSMA study, 200 of
which were against the primary outcome measure, the MHFMS.
Candidate markers from this group included 97 plasma proteins,
59 plasma metabolites and 44 urine metabolites.
A key feature of this study is the combination of measures of
historical (SMA type) and current function, in a cohort in which
recruitment was targeted specifically to minimize the correlation
between the two. SMA is unique among monogenic disorders for
having its phenotype severity modified by production of a smaller
quantity of an identical SMN protein produced from the highly
homologous SMN2 gene present in all individuals with SMA. In
monogenic neurodegenerative disorders the level of impairment
can be modeled as a function of residual activity of the mutated
gene and the effect of other (genetic and environmental) factors
that modify its impact. Strong association of an identified analyte
to MHFMS more than SMA type suggests its relationship to the
factors involved in phenotype expression other than SMN, or to
more downstream consequences of the debility associated with
SMA type or MHFMS.
As there were no a priori assumptions as to what class of analyte
(transcript, protein or metabolite) would likely generate biomark-
ers associated with the MHFMS, a broad set were selected to both
maximize class distribution while minimizing experimental error.
This approach has been used in biomarker discovery previously in
models of atherosclerosis [51–53] and hepatotoxicity [38,54].
Cohort Recruitment in SMA Clinical Studies
A number of lessons were learned in the clinical phase of this
project. Rapid enrollment was enhanced by a competitive process
with weekly reports to participating sites that encouraged, and
later constrained, recruitment to needed patient groups based
upon age, SMA type and gender. Recruitment was further
enhanced by the support of patient advocacy groups, and the
assistance of International Spinal Muscular Atrophy Patient
Registry at Indiana University to identify subjects interested in
participating in the study. One important barrier to enrollment,
particularly in weaker individuals with SMA Type I who were the
most difficult to recruit, was the exclusion of patients taking
Table 3. Results from primary outcome analysis across all seven ‘‘omic’’ platforms.
Sample Type Platform Number of Assayed Analytes
Number of ‘‘Markers’’ that Associate with
MHFMS
Plasma LC-MALDI-MS/MS Proteomics 701 97
Plasma Lipid LC/MS Metabolomics 71 12
Plasma GC/MS Metabolomics 160 28
Plasma Amino Acid Analysis 37 9
Plasma Free Fatty Acid Analysis 47 10
Urine GC/MS Metabolomics 168 44
Whole Blood Affymetrix Exon Array 807,038 0
The overall number of hit markers identified that significantly associate with the MHFMS primary outcome measure is 16.9% when the exon array analysis is excluded.
doi:10.1371/journal.pone.0035462.t003
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not be obtained, in each case a function of difficult venous access
or the limited cooperation possible from children. As expected,
recruitment was slower in the winter months and around holidays.
The possibility of biases against the population of individuals with
SMA as a whole that were introduced by the inclusion and
exclusion criteria cannot be excluded. As only children age 2 to 12
years were included, for reasons described previously, the more
typical SMA Type I infants with severe weakness were largely
excluded as they would not in many cases still be alive or meet the
inclusion criteria. Thus the Type I population in this study is
potentially biased towards the stronger and more stable subjects.
The study group identified several issues associated with
sampling procedures in this study including an apparent lack of
appropriate sample collection and storage materials for pediatric
subjects, lack of reference standards for pediatric subjects and a
paucity of data on sample handling and analytics for biomarker
and pediatric studies. This is an untapped area of research that is
of critical importance with increasing attention to therapeutics
programs for children. For this study population the only
systematic issue identified was that the smaller children were
more often the ones in whom it was difficult to obtain samples. In
future studies of this type using experts in venipuncture for small
children may improve the rate of successful sample procurement.
Figure 1. Illustration of the top 5 markers as candidate biomarkers by age. The natural log intensity of the protein abundance of CILP2,
TNXB, COMP, ADAMTSL4 and CLEC3B are shown by age (Panels A-E) across Types. Panels A-E generally show a trend for type but not age.
doi:10.1371/journal.pone.0035462.g001
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Measures
One limitation of this study is the use of a scale that may not
differentiate among the lowest (‘‘floor effect’’) and highest (‘‘ceiling
effect’’) functioning subject as the primary outcome measure of
motor function for correlation to biomarker analyte values. The
MHFMS is designed to assess function in children with Type II
SMA. As a consequence, it cannot assess the variety of differences
in motor function of those with SMA who are unable to sit (Type I
infants, and those with SMA who once sat but have since lost this
ability) or who are able to stand and walk (i.e. those with Type III
SMA who retain this defining motor ability). Our study strategy
was thus to use the MHFMS as the primary outcome measure for
regression to analyte values, but to also evaluate analyte
regressions to other measures of function (Table 1 and Table S1)
that assess ability outside of the MHFMS range, or complement
the MHFMS by assessing other motor functions not targeted by
items in the MHFMS.
The restricted range of the MHFMS also introduces potential
error in the strength of associations found. By design, our study
cohort included subjects who scored the constrained maximum or
Figure 2. Illustration of the top 5 markers as candidate biomarkers by MFMHS. The natural log intensity of the protein abundance of CILP2,
TNXB, COMP, ADAMTSL4 and CLEC3B are shown by MHFMS (Panels A-E) across Types. Panels A-E again show a trend for type and MHFMS. Panels F-J
shows the box plot distribution by type.
doi:10.1371/journal.pone.0035462.g002
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increase (positive) or decrease (negative) slopes of identified
associations, and alter the correlation strength in an unknowable
way, we conducted a post hoc test analysis of the primary outcome
measure removing subjects having these border values. This post
hoc approach, by decreasing the number of subjects, will
necessarily decrease the power of the statistical models. Nonethe-
less, the strongest hits as ranked by Q-value were reproduced
when the border-score subjects were removed from the analysis.
Given the restricted range of the MHFMS and some of the
supplemental measures, it is notable that identified candidate
makers that were found to discriminate between high or low
functioning SMA subjects were generally consistent across all
outcome measures employed in the study (MHFMS, Current
Level of Function, Respiratory Support, and Feeding Method).
The biological importance of these findings needs to be explored:
these correlations may indicate distinct phases of disease patho-
genesis, different pathological mechanisms, or even the temporal
importance of SMN during early motor development. However,
the very existence of markers that distinguish between Type I and
Type II, Type II and Type III and between Type III and control
subjects is highly encouraging of the potential to develop
pharmacodynamics biomarkers from this list. Whether these
candidate markers have any predictive value for different
therapeutic mechanisms of action remains to be determined.
Protein, Metabolite, and Transcript Findings
Plasma protein candidate markers were generally the most
significant markers of the set in the univariate analysis against the
MHFMS as well as across other outcome measures. While
Figure 3. Illustration of the top 5 markers as candidate biomarkers by Type. The natural log intensity of the protein abundance of CILP2,
TNXB, COMP, ADAMTSL4 and CLEC3B are shown (Panels A-E) by Type. Error bars are expressed as standard errors.
doi:10.1371/journal.pone.0035462.g003
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candidate markers from this sample set are undergoing further
post hoc evaluation to assess potential confounding effects of
special diet and nutritional supplements provided to the majority
of the Type I SMA subjects. If confirmed, these metabolomic
associations to clinical markers of severe motor function impair-
ment may undermine both their potential usefulness as candidate
markers and enthusiasm for further developmental work of their
validation.
Unexpectedly, there were no widespread changes in gene
expression that correlated with disease severity or comparison of
SMA to controls. We also did not observe a significant difference
in SMN expression levels between SMA patients and control
subjects. By using another method of transcript quantification,
lower levels of SMN-FL transcripts were demonstrated for this
cohort patients compared to controls (see companion paper,
Crawford, et al. [61]). This discrepancy is most likely due to a
difference in the methodology used to quantify the levels of SMN
transcripts. The absence of widespread changes in gene expression
or splicing in blood suggests that the degree of reduction of the
SMN protein levels in this tissue is not sufficient to cause dramatic
changes on the level of gene expression or splicing, at least in
peripheral blood mononuclear cells. This would be consistent with
the fact that blood and other tissues of the body do not typically
exhibit significant disturbances of cellular or organ function except
in the Type I cohort. Limited SMN expression at the level of
symptomatic SMA appears to predominantly affect motor
neurons, and possibly some other neuronal types [55]. Pathologic
changes have been observed in the context of extreme reduction of
SMN production in every tissue that has been investigated, but the
basis for the increased vulnerability of motor neurons is unknown
[55]. The study did identify a decrease in the expression of the
NLR family inhibitory protein (NAIP), which is consistent with the
genomic deletion of SMN1 together with neighboring NAIP in
SMA alleles associated with severe type [56,57].
The Path to Validation and Qualification and the
Biological Utility of the Plasma Biomarkers
The BforSMA project is designed to be an unbiased approach
to generating a dataset that can be used for biomarker
identification and also post-hoc hypothesis testing. On one hand,
an unbiased ascertainment of large data sets will, by design,
generate false positives.
When one attempts to determine a role in disease for the
statistically significant biomarkers discovered in plasma a few
caveats must be emphasized. Any biological differences recorded
in the plasma are likely to be downstream, and in some cases far
downstream, from the original disease perturbation in SMA, at the
motor neuron or neuromuscular junction. A significant perturba-
tion from the norm, as related to a measure of motor function, can
reflect any of a number of biological processes that affect bone and
other connective tissues and not be indicative of a specific
Table 4. Top 20 univariate MHFMS markers across platforms.
Platform Symbol Description Slope STD P-value Q-value UCL LCL
Proteomics CILP2 Cartilage intermediate layer
protein 2
53.32 4.57 1.95E-20 1.07E-17 44.26 62.38
Proteomics TNXB Tenascin XB 62.91 6.09 1.66E-17 4.56E-15 50.83 74.99
Proteomics COMP Cartilage oligomeric matrix
protein
60.78 6.04 7.02E-17 1.29E-14 48.80 72.76
Proteomics ADAMTSL4 ADAMTSlike 4 33.91 3.87 4.84E-14 6.66E-12 26.24 41.58
Proteomics CLEC3B C-type lectin domain family 3,
member B
56.47 6.55 9.31E-14 1.02E-11 43.49 69.46
AAA Glu L-Glutamic acid 222.86 2.76 4.86E-13 9.73E-11 228.34 217.38
GC/MS Glu L-Glutamic acid 221.10 2.57 6.29E-13 9.73E-11 226.19 216.01
Proteomics TNXB Tenascin XB 53.20 7.17 3.68E-11 3.37E-09 38.98 67.41
GC/MS Asp L-Aspartic-acid 225.46 3.58 1.48E-10 1.53E-08 232.56 218.37
Proteomics DPP4 Dipeptidylpeptidase 4 65.10 10.19 5.61E-09 4.41E-07 44.88 85.32
Proteomics THBS4 Thrombospondin 4 51.46 8.28 1.15E-08 7.89E-07 35.04 67.88
GC/MS C10:0-fatty-acid 27.47 1.34 2.16E-07 1.67E-05 210.14 24.81
AAA Asp L-Aspartic-acid 217.76 3.27 3.82E-07 2.12E-05 224.25 211.27
Lipid 24:1 Sphingomyelin 27.88 1.46 4.60E-07 2.12E-05 210.78 24.98
FFA C10:0 (capric) 26.47 1.20 4.80E-07 2.12E-05 28.86 -4.08
Proteomics CDH13 Cadherin 13 42.61 7.89 4.57E-07 2.79E-05 26.95 58.27
Proteomics CRTAC1 Osteomodulin 46.61 8.80 6.95E-07 3.48E-05 29.15 64.07
Proteomics OMD Cartilage acidic protein 1 46.94 8.81 6.67E-07 3.48E-05 29.45 64.44
Proteomics PEPD Peptidase D 25.14 4.91 1.45E-06 6.63E-05 15.40 34.87
Proteomics F13B Coagulation factor 13
polypeptide B
41.57 8.18 1.70E-06 7.20E-05 25.35 57.79
Table is ordered by lowest to highest Q-values. Only plasma markers are represented, as these were the markers with the lowest Q-values. Unknown metabolites were
removed from this summary table but the full plasma and urine metabolite and proteomic datasets are available in the Tables S3, S4, S5. AAA – Amino acid analysis; FFA
– Free fatty acid; Q-VALUE – significance corrected for the effect of multiple comparisons; STD – Standard deviation; UCL – Upper 95% confidence limit; LCL – lower 95%
confidence limit (on the value of slope). Slope values are given as positive and negative (-) values. *These are distinct isoforms detected by the LC/MS method.
doi:10.1371/journal.pone.0035462.t004
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reflect reduced levels of SMN protein expression. From a
biomechanical perspective changes in bone components are not
surprising in SMA. Tendons transmit contractile muscle forces to
bone. In a state of muscle weakness, such as in SMA, these forces
to bone are less, especially in the long bones of the limbs in the
non-ambulatory SMA types I and II. As such, bone remodeling
processes, an especially important process in a growing child, are
altered. Thus, a case can be made for the functional differences in
bone growth remodeling between the weakest and strongest
children. Cartilage intermediate layer protein 2 (CILP2), a marker
with a strong association to the Hammersmith Functional Motor
Score, may not have a direct relationship to motor neuron biology.
However it is notable that CILP2, like other high-scoring plasma
protein markers such as COMP, TNXB, THBS4, SPP1, COL2A1
to name a few, are associated with connective tissue development
(cartilage matrix synthesis in the case of CILP2) and bone and
joint disorders. SMA patients have been reported to have bone
density losses that are correlated to age, frequent fractures, and in
severe cases congenital fractures [58]. It is possible that the bone
and joint protein signature present in the BforSMA study relates to
secondary connective tissue sequelae in the disease. In addition,
Shanmurgan et al. found that the SMN protein is a binding
partner to osteoclast stimulating factor (OSF), a protein involved in
osteoclast development and bone resorption which raises the
possibility of a direct SMN-related perturbation in bone in SMA.
On the other hand, biomarkers like CILP2 identified in this
study have the advantage of being independent of specific
hypotheses about pathophysiology. While some biomarkers may
initially attract attention based upon arguments arising from
biological plausibility, the role of other potentially valuable
biomarkers may not be immediately obvious. Much further work
will be necessary to identify analytes on this list that can improve
the understanding of SMN deficiency on cellular pathophysiology,
or to develop a biomarker that can be valuable to the efficient
performance of SMA treatment trials, whether of a specific SMN-
enhancing agent or of a therapy targeting other steps of the disease
cascade.
Several questions remain to be answered. Will a candidate
biomarker be stable over time, and is measurement stability
influenced by technical issues such as sample handling or short-
term biologic factors such as diet or time of day? Will changes in
candidate biomarkers track meaningful changes in impairment,
such that it may be an early surrogate for the consequences of
SMA as it is experienced by patients? Or will changes over time
reflect other processes (e.g. sarcopenia) that are not related to
motor function and therefore may not be informative in the
domain of interest? By including a cohort of age and gender
matched subjects with other motor impairments relating to
localizable neurologic conditions (e.g. myopathy or cerebral palsy),
a confirmatory study may help to clarify if changes in biomarkers
are specific to SMA or instead relate better to downstream
consequences of the disorder. The power of any one biomarker
might be insufficient for use in treatment trials, but the
contribution of a panel of qualified biomarkers that independently
contribute to clinical assessment might be of value to explore.
Experimental subjects in this cohort were all healthy at the time of
enrollment and cared for at major academic centers where the
care of children with SMA is a priority. Would a candidate
biomarker perform as well in a larger population of children with
SMA compared to those in the BforSMA study? Not all of the
development need be in the clinical laboratory. Improvements in
measurement of clinical function [59], better matching them to the
underlying neuronal dysfunction, or extending their range so that
a broader range of children with SMA can be assessed, may yield
improvement in biomarker performance characteristics.
The path of a biomarker, from candidate identified by single-
visit correlation to a clinical feature to becoming a qualified
biomarker with well-characterized meaning, is necessarily multi-
faceted and complicated. Confirmation of these observations will
require that we reproduce findings in other prospectively collected
samples from SMA cohorts that share features with the BforSMA
population. Because the BforSMA study was a single-visit effort, to
truly determine whether these candidate markers are prognostic
and can change with SMA status, they must be tested over time in
longitudinal assessments. Such projects are now in development
with new analytic methods that can more readily be scaled to
clinical research protocols.
Support and further validation of biomarkers can come from
other areas, such as confirmation in SMA animal models. The
assembly of biomarker networks of metabolites, proteins and
transcripts based on statistical significance has the potential to be
partially internally validating, as it may identify coordinated
cellular or tissue physiologic strain of pathophysiologic importance
not apparent from any single metabolite or platform of analysis.
Further evaluation of identified candidates to understand their
pathophysiologic relationship to SMN, or to the consequences of
neuromuscular impairment, might be possible by further bio-
marker study with SMA patients in which muscle physiology
outcome measures that conceptually describe the motor unit
function and structure, or comparison to SMA animal models or
to other disease control human populations. In particular, testing
any hypothesis that a subset of these markers are primarily SMA-
specific versus being consequences of secondary changes down-
stream of neuromuscular disease would be valuable for further
study. However, it is important to emphasize that whether they are
primary or secondary to SMA pathophysiology, any markers that
strongly associate with SMA outcomes over time and replicate in
different studies will be of great value in clinical trials and patient
management.
Finally, once a subset of the markers is confirmed in other
populations and prospective studies, efforts can be devised to
determine if combining markers across platforms with SMA
clinical characteristics could produce a multicomponent predictive
model that has even stronger associations with SMA status or is
possibly better able to predict outcomes or response to interven-
tions. These types of markers have proven very powerful in the
cancer field and with the emergence of new SMA drug trials, there
is potential for developing information about multicomponent
models for drug response and even stratify responder populations
with some of these SMA candidate markers after they have been
confirmed and shown to be responsive to therapy [15,60].This
BforSMA project has generated a resource of protein and
metabolite candidate biomarkers for future study. The effort has
taken advantage of recent technological developments that
enhance our ability to measure a broad range of proteins,
metabolites and transcripts from a single blood sample; a well-
characterized set of SMA subjects in whom function and age are
independent; and the advanced bioinformatics and biostatistical
resources necessary to support the project. The data and samples
generated by this effort will be an important resource for the field
and future studies, with the additional value of serving as a single
visit ‘test run’ for an industry-style multicenter trial for several
SMA clinical sites. The full dataset from the study will be made
available to all investigators in an accessible format to be used as a
resource to address the many questions raised by our findings.
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